David Augustsson

This profile gathers the share dealings of David Augustsson in Oncopeptides AB, where the filings describe the role as board member. In total, 18 filings cover trades dated from 10 August 2023 to 17 March 2026.

Every open-market trade on record is a purchase: 13 purchases worth €7,924, and no sale. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Outside the open market, there are 2 share grants. Since January 2026: 4 purchases and no sales on the market.

The median purchase comes to €546. Clusters matter here: 1 out of 9 purchases overlapped with buying by a colleague within 30 days. Purchases made close together by different insiders form what is called a cluster.

Most recently, on 17 March 2026, the filings show an open-market purchase worth €152 in Oncopeptides AB. Half of the filings or more reach the Finansinspektionen feed on the day of the trade. Under the Market Abuse Regulation, managers have three business days to notify their trades. This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.